Shiraki K, Horiuchi K, Asano Y, Yamanishi K, Takahashi M
Department of Virology, Osaka University, Japan.
J Med Virol. 1991 Feb;33(2):128-32. doi: 10.1002/jmv.1890330212.
The Oka varicella vaccine strain can be differentiated from wild-type strains by its unique restriction endonuclease fingerprinting (REFP: HpaI-K and EcoRI-P) pattern of the gpV-coding region of the varicella-zoster virus (VZV) genome. VZV-DNAs from patients with complicated clinical courses related to vaccination were examined to determine whether they were vaccine-derived or wild-type. A virus was isolated from a one year-old boy with acute lymphocytic leukemia (ALL) who developed typical varicella 28 days after vaccination (case A). Another virus was isolated from a four-year-old boy without clinical symptoms following household contact with varicella patients at the age of two months, and he developed zoster 14 months after vaccination (case B). Also, two strains (OK1 and OK2) were isolated from household contacts (mother and sister) with a vaccine with ALL in Oklahoma who developed varicella 18 days after vaccination (case C). In case C, BgII-REFP did not determine conclusively whether the two strains (OK1 and OK2) were vaccine-derived or wild-type because the patterns obtained were different from both the Oka varicella vaccine strain and American wild-type strains [Gelb et al., Journal of Infectious Diseases, 155:633-640, 1987]. All VZV strains examined in the present study were identified as wild-type by our method using HpaI-K and EcoRI-P fragments as marker fragments. Thus it is becoming evident that REFP using HpaI and EcoRI endonucleases is a convenient and reliable means of distinguishing between the Oka vaccine virus strain and wild-type viruses isolated from individuals developing vesicular rashes shortly and long after varicella vaccination.
通过其水痘 - 带状疱疹病毒（VZV）基因组gpV编码区独特的限制性内切酶指纹图谱（REFP：HpaI - K和EcoRI - P）模式，可将Oka水痘疫苗株与野生型毒株区分开来。对与疫苗接种相关的复杂临床病程患者的VZV - DNA进行检测，以确定它们是疫苗衍生型还是野生型。从一名患有急性淋巴细胞白血病（ALL）的1岁男孩体内分离出一种病毒，该男孩在接种疫苗28天后出现典型水痘（病例A）。另一种病毒从一名4岁男孩体内分离出来，该男孩在2个月大时与水痘患者有家庭接触后无临床症状，在接种疫苗14个月后出现带状疱疹（病例B）。此外，从俄克拉荷马州一名患有ALL的疫苗接种家庭接触者（母亲和妹妹）体内分离出两种毒株（OK1和OK2），他们在接种疫苗18天后出现水痘（病例C）。在病例C中，BgII - REFP无法最终确定这两种毒株（OK1和OK2）是疫苗衍生型还是野生型，因为获得的图谱与Oka水痘疫苗株和美国野生型毒株均不同[Gelb等人，《传染病杂志》，155:633 - 640，1987]。本研究中检测的所有VZV毒株通过我们使用HpaI - K和EcoRI - P片段作为标记片段的方法被鉴定为野生型。因此，越来越明显的是，使用HpaI和EcoRI内切酶的REFP是区分Oka疫苗病毒株与水痘疫苗接种后不久和很久出现水疱疹的个体所分离出的野生型病毒的便捷可靠方法。
